JP2009510091A5 - - Google Patents

Info

Publication number

JP2009510091A5

JP2009510091A5 JP2008533609A JP2008533609A JP2009510091A5 JP 2009510091 A5 JP2009510091 A5 JP 2009510091A5 JP 2008533609 A JP2008533609 A JP 2008533609A JP 2008533609 A JP2008533609 A JP 2008533609A JP 2009510091 A5 JP2009510091 A5 JP 2009510091A5

Authority

JP

Japan

Prior art keywords

composition

amniotic

purified

human

angiogenesis

Prior art date

2006-09-27

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000000203 mixture Substances 0.000 claims 20
• 238000000034 method Methods 0.000 claims 11
• 239000000463 material Substances 0.000 claims 8
• 206010061218 Inflammation Diseases 0.000 claims 6
• 210000001691 amnion Anatomy 0.000 claims 6
• 230000004054 inflammatory process Effects 0.000 claims 6
• 230000033115 angiogenesis Effects 0.000 claims 5
• 230000002401 inhibitory effect Effects 0.000 claims 4
• KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 3
• 229920002674 hyaluronan Polymers 0.000 claims 3
• 229960003160 hyaluronic acid Drugs 0.000 claims 3
• 210000002889 endothelial cell Anatomy 0.000 claims 2
• 238000009472 formulation Methods 0.000 claims 2
• 235000015110 jellies Nutrition 0.000 claims 2
• 239000008274 jelly Substances 0.000 claims 2
• 210000002826 placenta Anatomy 0.000 claims 2
• 108090000623 proteins and genes Proteins 0.000 claims 2
• 230000036573 scar formation Effects 0.000 claims 2
• 239000007787 solid Substances 0.000 claims 2
• GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 claims 1
• 102000008070 Interferon-gamma Human genes 0.000 claims 1
• 108010074328 Interferon-gamma Proteins 0.000 claims 1
• 206010028980 Neoplasm Diseases 0.000 claims 1
• 101700026522 SMAD7 Proteins 0.000 claims 1
• 102000049873 Smad7 Human genes 0.000 claims 1
• 102000046299 Transforming Growth Factor beta1 Human genes 0.000 claims 1
• 101800002279 Transforming growth factor beta-1 Proteins 0.000 claims 1
• 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
• 230000003213 activating effect Effects 0.000 claims 1
• 206010064930 age-related macular degeneration Diseases 0.000 claims 1
• 229960000711 alprostadil Drugs 0.000 claims 1
• 230000003110 anti-inflammatory effect Effects 0.000 claims 1
• 230000006907 apoptotic process Effects 0.000 claims 1
• 206010003246 arthritis Diseases 0.000 claims 1
• 230000015572 biosynthetic process Effects 0.000 claims 1
• 201000011510 cancer Diseases 0.000 claims 1
• 230000000694 effects Effects 0.000 claims 1
• 230000004528 endothelial cell apoptotic process Effects 0.000 claims 1
• 108010093564 inter-alpha-inhibitor Proteins 0.000 claims 1
• 229960003130 interferon gamma Drugs 0.000 claims 1
• 210000002540 macrophage Anatomy 0.000 claims 1
• 208000002780 macular degeneration Diseases 0.000 claims 1
• 238000013508 migration Methods 0.000 claims 1
• 230000005012 migration Effects 0.000 claims 1
• 230000014399 negative regulation of angiogenesis Effects 0.000 claims 1
• 229920000642 polymer Polymers 0.000 claims 1
• BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 claims 1
• GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 claims 1
• XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 claims 1
• BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 claims 1
• 102000004169 proteins and genes Human genes 0.000 claims 1
• 238000000746 purification Methods 0.000 claims 1
• 230000011664 signaling Effects 0.000 claims 1
• 238000013268 sustained release Methods 0.000 claims 1
• 239000012730 sustained-release form Substances 0.000 claims 1
• 102000003390 tumor necrosis factor Human genes 0.000 claims 1